Stocks on the Rise

Wise (+10%): The British fintech posted better-than-expected results for its fiscal Q3. Management reaffirmed its annual targets, now aiming for a PBT margin at the higher end of the range. "The 2026 P/E is back below 20, which is appealing, especially given the company's structural growth," notes AlphaValue.

Inficon (+7%): Deutsche Bank upgraded from hold to buy, raising its price target from 95 CHF to 140 CHF.

Jacquet Metals (+6%): Oddo BHF upgraded from neutral to outperform, with a price target raised from 20 to 27 EUR.

Abivax (+4%): According to La Lettre, in addition to Eli Lilly, Swedish-British pharma giant AstraZeneca is also reportedly in the running to acquire the French biotech. The market remains cautious, waiting to see proof after the stock's sharp rise and speculation surrounding Lilly.

Salzgitter : The German steelmaker benefits from a double upgrade by Oddo BHF, which moved from underperform to outperform, raising its target from 58 to 64 EUR.

Virbac (+3%): The veterinary lab saw annual revenue climb 7.9% to 1.465 billion euros at constant scope and exchange rates. At actual exchange rates, revenue growth was just 1.9%. "A solid trend, impacted by FX," summarizes Oddo BHF. TP ICAP, for its part, finds the 2026 outlook reassuring.

Renault (+2.7%): The automaker has two positive developments today. First, it announced global sales of 2,336,807 vehicles in 2025, an increase of 3.2% in a market up 1.6%. Additionally, according to L'Usine Nouvelle, Renault is preparing to produce military drones at its Le Mans and Cléon sites, a project that "could open up a market worth about one billion euros over 10 years with the DGA," according to the media outlet.

Stocks on the Decline

Hypoport (-10%): The decline in real estate financing in Q4 weighs on the German group's shares. This marks a notable shift from the rest of the year's momentum, as this division posted 13% growth in 2025.

Valneva (-6.5%): The lab has voluntarily withdrawn its market authorization and clinical trial applications in the United States for its chikungunya vaccine, IXCHIQ, whose license was suspended by the FDA in August. "This news confirms our scenario of abandoning the U.S. market for the IXCHIQ vaccine. This is a significant loss for Valneva, as the American market remains the highest value-added market," comments Portzamparc.

Eutelsat (-5%): Morgan Stanley maintains an equal-weight rating, with a price target cut from 2.73 to 2.50 EUR.

Logitech (-5%): Morgan Stanley downgraded its recommendation on the Swiss group from equal-weight to underweight (target cut from 107 to 89 USD on the ADR). With less impact, Deutsche Bank maintains a hold rating, lowering its target from 90 to 80 CHF.

Carl Zeiss Meditec (-4%): Goldman Sachs downgraded from buy to neutral, with a price target reduced from 54 to 42 EUR. The American broker also downgraded Fresenius Medical Care from buy to neutral, reducing the price target from 55 to 40 EUR.